Please assess the completion status of the following clinical trial:

Trial Title: SOIBD Collagenous Colitis Maintenance Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent,~2. Patients aged \>= 18 years,~3. Histologically established diagnosis of collagenous colitis (CC) defined as:~   1. Thickened sub-epithelial collagen layer \>= 10 µm on well-orientated sections,~  2. Increased amount of inflammatory cells indicating chronic inflammation in the lamina propria,~4. History of non-bloody, watery diarrhoea for more than 2 weeks prior screening in patients with newly diagnosed collagenous colitis, or history of clinical relapse for more than 1 week prior screening in patients with previously established collagenous colitis,~5. A mean of \>= 3 stools/day, thereof a mean of \>= 1 watery stools/day, during the week prior baseline,~6. Women of child-bearing potential and being heterosexually active have to apply appropriate contraceptive methods, e.g., hormonal contraception, intrauterine device (IUD), double-barrier method of contraception (e.g., use of a condom and spermicide), or partner has undergone vasectomy. The investigator is responsible for determining whether the subject has adequate birth control for study participation.~Exclusion Criteria:~1. Other significant abnormalities at colonoscopy that may have been the cause of diarrhoea, with the exception of colonic diverticulosis and polyps \< 2 cm,~2. Infectious cause of diarrhoea,~3. Untreated active celiac disease,~4. Clinical suspicion of drug-induced collagenous colitis,~5. Any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder,~6. Abnormal hepatic function (ALT or ALP \> 2.5 x upper limit of normal \[ULN\]), liver cirrhosis, or portal hypertension,~7. Local intestinal infection,~8. Radiation therapy towards the abdominal or pelvic region,~9. Diabetes mellitus, infection, glaucoma, tuberculosis, peptic ulcer disease, or hypertension if careful medical monitoring is not ensured,~10. Known established cataract,~11. Known hereditary problems of galactose or fructose intolerance, glucose-galactose malabsorption, sucrase-isomaltase insufficiency, Lapp lactase deficiency, or congenital lactase deficiency,~12. Established osteoporosis with T-score \< -2.5,~13. Pregnancy or lactation,~14. History of cancer in the last five years,~15. History of significant bowel resection,~16. Therapy with immunomodulators (azathioprine, 6-mercaptopurine, or methotrexate) in the last 3 months,~17. Treatment with oral, rectal, or intravenous corticosteroids including budesonide in the last month,~18. Known intolerance/hypersensitivity to study drug or drugs of similar chemical structure or pharmacological profile,~19. Patients who are unable to adhere to the study visit schedule and other protocol requirements according to the judgement of the investigator,~20. Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Alternating daily dosing with 2 x 3 mg budesonide capsules OD and 1 x 3 mg budesonide capsule OD every second day
- B (Type: PLACEBO_COMPARATOR): Alternating daily dosing with 2 placebo capsules OD and 1 placebo capsule OD every second day.

Based on this trial design, predict the completion outcome and termination type (if applicable).